Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar in elderly type 2 diabetes mellitus: effects on T cell subsets and endothelial progenitor cells
ChiCTR2200064497Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Chengdu Medical College
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of chiglitazar in type 2 diabetes mellitus (T2DM) and diabetic angiopathy (DPA) (2 arms), sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoints: T cell subsets, Endothelial progenitor cells and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
chiglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic angiopathy (DPA)
Beyond the preview
Go deeper on ChiCTR2200064497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064497.